News & Press Releases Swedish

Styrelseledamot köper ytterligare aktier i Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) (“ChemoTech”) meddelar idag att Robin Sukhia, styrelseledamot, har köpt ytterligare 3 000 aktier för cirka 75 500 SEK över börsen. Hans totala innehav uppgår nu till 13 000 aktier i ChemoTech.

Read more

Scandinavian ChemoTech startar en förstudie i USA

Idag har ChemoTech tecknat ett avtal med det amerikanska företaget Diversified Consultant Group LLC som kommer att ansvara för att genomföra en förstudie. Denna studie är utformad för att identifiera hur ChemoTech ska agera i sin "Go-to-Market" -strategi när Bolaget lanserar sin produkt vetIQure i USA.

Read more

Styrelseledamot köper ytterligare aktier i Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) (“ChemoTech”) meddelar idag att Martin Jerndal, styrelseledamot och större aktieägare, har köpt ytterligare 6 000 aktier för cirka 154 500 SEK över börsen. Hans totala innehav uppgår nu till 588 695 aktier i ChemoTech.

Read more

News & Press Releases English

Board member buys additional shares in Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) (“ChemoTech”) announces today that Robin Sukhia, board member, has bought further 3,000 shares for approximately SEK 75,500 over the stock exchange. His total holding now amounts to 13,000 shares in ChemoTech.

Read more

Scandinavian ChemoTech starts a feasibility study in the USA

Today Scandinavian ChemoTech has signed an agreement with the US based company Diversified Consultant Group LLC that will be responsible for performing a feasibility study. This study is aiming to identify how Scandinavian ChemoTech should design a “Go-to-Market” strategy when launching its animal care product vetIQure in the USA.

Read more

Board member buys additional shares in Scandinavian ChemoTech AB

Scandinavian ChemoTech AB (publ) (“ChemoTech”) announces today that Martin Jerndal, board member and major shareholder, has bought further 6,000 shares for approximately SEK 154,500 over the stock exchange. His total holding now amounts to 588,695 shares in ChemoTech.

Read more

ChemoTech Videos

ChemoTech presents at Småbolagsdagarna /Aktiespararna 9 June 2021. Spoken language is Swedish but the presentation is in English.

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish)

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both TSE- Tumour Specific Electroporation and the first generation electrochemotherapy for the treatment of a range of different types of tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.